Meeting
2023 ASCO Annual Meeting
Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC).
Authors
Qianyu Yuan
Flatiron Health, New York, NY
Qianyu Yuan , Emily Castellanos , Erin Fidyk , Karen Schwed , Melissa Estevez , Sheila Nemeth , Robin Linzmayer , Aaron B. Cohen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1031)
DOI
10.1200/JCO.2023.41.16_suppl.1031
Abstract #
1031
Poster Bd #
252
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).
First Author: Erica Michelle Stringer-Reasor
Poster
2020 ASCO Virtual Scientific Program
SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).
First Author: Santiago Escrivá
Poster
2018 ASCO Annual Meeting
![A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].](https://d201v5jt9ylckg.cloudfront.net/214/12940/161815/161815_poster_pv.jpg)
A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].
First Author: Stephen K. L. Chia
Poster
2017 ASCO Annual Meeting
First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).
First Author: Maria Alsina